Loading

Press Releases

About Avicanna

Avicanna is a Canadian commercial-stage biopharmaceutical company established in cannabinoid research, development, and evidence-based products for the global consumer, as well as medical and pharmaceutical market segments. In leading global cannabinoid advancements, Avicanna conducts most of its research in Canada at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, located in the MaRS Discovery District. The Company actively collaborates with leading Canadian academic and medical institutions. Avicanna has established an industry-leading scientific platform including advanced R&D and clinical development which has led to the commercialization of over twenty products across four main market segments:

  • Medical Cannabis & Wellness Products: RHO Phyto TM
  • CBD Derma-Cosmetic Products: Pura H&WTM or Pura EarthTM
  • Pharmaceuticals: TruneroxTM
  • Cannabis Raw Materials, Seeds, and Bulk Formulations: AureusTM
May 6, 2022

Avicanna Announces Closing of Strategic Private Placement

TORONTO, May 06, 2022 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has closed a strategic non-brokered private placement offering of 4,210,931 ‎‎units of the Company (the “Units”) at a price of $0.35 per Unit for aggregate gross …

April 5, 2022

Avicanna Expands its Derma-Cosmetics Brand Pura H&W™ into the European Union through a Partnership with Bio-Gate AG

TORONTO, April 05, 2022 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development  …

March 31, 2022

Avicanna Announces Filing of Annual Financial Statements for Year Ended December 31, 2021

TORONTO, March 31, 2022 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of …

March 31, 2022

Avicanna Announces Closing of Non-Brokered Private Placement

TORONTO, March 31, 2022 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products …

Avicanna Enters into a Strategic Partnership with Tetra Bio-Pharma – February 10, 2022
Avicanna Provides Q4-2021 Results and Corporate Highlights as well as Fiscal 2022 Guidance – February 02, 2022
Avicanna Announces Closing of Non-Brokered Private Placement of Convertible Debenture Units– January 28, 2022
Avicanna Enters Master Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A.– January 14, 2022
Avicanna Announces the Appointment of Stephen Kim as Chief Legal Officer & General Counsel– January 10, 2022
Avicanna Announces Changes to its Board of Directors– Jan. 4, 2022
Avicanna Completes First Commercial Export of CBG from Colombia to Czech Republic– Dec. 24, 2021
Avicanna Launches its Clinically Backed CBD Derma-cosmetics Brand, Pura H&W, in the United States in Partnership with Red White and Bloom– Dec. 22, 2021
Avicanna and Harrington Wellness launch re+PLAY™ branded CBD topicals products in Canada– Dec. 20, 2021
Avicanna to Participate in the Lytham Partners Winter 2021 Investor Conference– Dec. 10, 2021
Avicanna Files a Patent to Protect its Advanced Oral Cannabinoid Platform and its Applications for Neurological Diseases– Dec. 06, 2021
Avicanna Enters into an Intellectual Property Licensing and Distribution Agreement with Established Pharmaceutical Company in Argentina– Nov. 30, 2021
Avicanna Expands its Medical Cannabis Brand RHO Phyto into the Caribbean Region with Initial Export to Barbados– Nov. 25, 2021
Avicanna Announces Filing of Interim Financial Statements for the Three-Month Period Ending September 30, 2021, Demonstrating Progressive Commercialization Results– Nov. 12, 2021
Avicanna Announces Resignation of Director– Nov. 11, 2021
Viola Brands Launches Nationwide in Canada through the Medical Cannabis by ShoppersTM online platform– Nov. 9, 2021
Avicanna Inc. to Host Third Quarter 2021 Investor Conference Call on November 12 and Announces Warrant Repricing– Nov. 8, 2021
Avicanna Announces Management Change– Nov. 5, 2021
Avicanna´s subsidiary obtains Good Agricultural and Collection Practices (“GACP”) Certification in Colombia– Nov. 4, 2021
Avicanna Completes Commercial Export of CBD Isolate and CBD Full Spectrum Psychoactive Derivatives from Colombia to Chile– Oct. 22, 2021
Avicanna Closes Non-Brokered Private Placement Raising $3.9 Million and Announces Warrant Repricing– Oct. 19, 2021
Avicanna Completes First Commercial Export of Feminized Cannabis Seeds from Colombia to Peru and Argentina– October 1, 2021
Avicanna Files US Patent Application for a Novel Cannabinoid Formulation in Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy– Sept. 24, 2021
Avicanna Completes Registration and Commercial Export of its Evidence-Based CBD Dermacosmetics Brand, Pura Earth, in Ecuador– Sept. 16, 2021
Avicanna Announces Filing of Interim Financial Statements for Period Ended June 30, 2021 and Provides Corporate Update– Sept. 10, 2021
Avicanna Announces Filing of Annual Financial Statements For Year Ended December 31, 2020– Sept. 03, 2021
Avicanna Completes First Commercial Export of Aureus Branded Full Spectrum Psychoactive CBD Cannabis Extracts to Brazil– Aug 27, 2021
Avicanna Expands Sales of Pura Earth and RHO Phyto Branded Topicals into Alberta’s Retail Channels– Aug 24, 2021
Avicanna Enters Partnership with Heritage Cannabis Holdings Corp. to Commercialize Evidence-Based Topical Products through Heritage’s Medical Cannabis Channels– Aug 11, 2021
Avicanna Announces Partial Revocation of Cease Trade Order and Proposed Financing– August 3, 2021
Avicanna Completes First Commercial Export of Aureus™ Branded THC Active Pharmaceutical Ingredients to Peru– August 3, 2021
Avicanna Completes First Commercial Export of Aureus™ Branded THC Extracts to Austria and Welcomes Colombian Government’s Progressive New Regulation on Cannabis– July 28, 2021
Avicanna Announces Change of Auditor– July 19, 2021
Avicanna and Bio-Gate Complete First Phase of Development on Cannabidiol (CBD) and MicroSilver BG™ Based Skin Care Products for Global Commercialization– June 29, 2021
Avicanna Announces Results of Annual General Meeting and Provides Corporate Update– June 24, 2021
Avicanna Expands The Canadian RHO Phyto Product Offerings With The Addition Of THC-Free High CBD Oral And Sublingual Formulation Across Medical And Adult Use Channels– June 15, 2021
Avicanna Announces Mailing of Management Information Circular and Proposed Board Changes– June 3, 2021
Avicanna’s Evidence-Based and Dermatologist Tested CBD Derma-Cosmetic Brand Pura Earth™ to be Launched in Adult-Use and Medical Channels Across Canada in Q2 2021.– May 26, 2021
Avicanna Makes RHO Phyto™ Medical Cannabis Products Available In Canadian Hospital Pharmacies Through Agreement with Sunnybrook Hospital – May 6, 2021
Avicanna Provides Bi-Weekly Update On Status Of Management Cease Trade Order – April 26, 2021
Avicanna Announces Receipt of Management Cease Trade Order and Provides Bi-Weekly Status Update – April 12, 2021
Avicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade Order – March 29, 2021
Avicanna Closes Non-Brokered Private Placement Raising $5.6 Million – Mar 4, 2021
Avicanna Announces Exercise And Closing Of Over-Allotment Option – Dec 31, 2020
Avicanna Announces Closing of Public Offering of Units – Dec 8, 2020
Avicanna Announces Overnight Marketed Public Offering of Units – Nov 12, 2020
Avicanna Reports Third Quarter 2020 Financial Results and Provides Corporate Update – Nov 12, 2020
Avicanna Closes Non-Brokered Private Placement Raising $2.7 Million – Aug 18, 2020
Avicanna Reports Second Quarter 2020 Financial Results and Provides Corporate Update – Aug 17, 2020
Avicanna Reports First Quarter 2020 Financial Results and Provides Corporate Update – May 25, 2020
Avicanna Closes Non-Brokered Private – Placement with Group of Strategic Investors and Announces Warrant Re-Pricing – April 21, 2020
Avicanna Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update – April 15, 2020
Avicanna Closes First Tranche of Private Placement – January 24, 2020
Avicanna Reports Third Quarter 2019 Financial Results – Nov. 14, 2019
Avicanna Completes its First Exportation of Cannabinoids from Colombia to Canada for Scientific Purposes – Aug 23, 2019
Avicanna Reports Second Quarter 2019 Financial Results – Aug 14, 2019
Avicanna Commences Trading on the TSX Under the Symbol “AVCN” – July 18, 2019
Avicanna Announces TSX Listing Date – July 16, 2019
Avicanna Announces Receipt for Final Prospectus and Conditional Approval for Listing on the TSX – July 10, 2019
Avicanna Closes Oversubscribed $22.1 Million Special Warrant Offering – April 18, 2019
Avicanna Announces Filing of Preliminary Prospectus – January 21, 2019
Avicanna Inc. Acquires 60% Stake in Colombian Medical Marijuana Firm Santa Marta Golden Hemp – August 16, 2018
Avicanna Completes 2nd Equity Financing & Welcomes New Strategic Shareholder – January 29, 2018
Avicanna Closes its First Equity Financing and Announces its Residency at Johnson & Johnson Innovation, JLABS @ Toronto – May 26, 2017

avica_white

480 University Ave, Suite 1502
Toronto, ON M5G 1V2
Canada

Want to stay up to date? Subscribe to receive email updates.

           
© 2017-2019 Avicanna Inc. All Rights Reserved.
Subscribe
SUBSCRIBE NOW

Sign up and join our Newsletter  

Stay updated with all latest
updates and news.
close-link